Breaking News Instant updates and real-time market news.

ENTA

Enanta

$43.43

-0.07 (-0.16%)

, ADXS

Advaxis

$3.91

-0.36 (-8.43%)

04:55
09/27/17
09/27
04:55
09/27/17
04:55

Cantor Fitzgerald to hold a conference

Global Healthcare Conference is being held in New York on September 25-27.

ENTA

Enanta

$43.43

-0.07 (-0.16%)

ADXS

Advaxis

$3.91

-0.36 (-8.43%)

AWR

American States Water

$50.68

-0.8 (-1.55%)

CDTX

Cidara Therapeutics

$8.05

0.2 (2.55%)

GEMP

Gemphire Therapeutics

$9.60

-0.04 (-0.41%)

ARRY

Array BioPharma

$11.29

-0.03 (-0.27%)

AUPH

Aurinia Pharmaceuticals

$6.11

-0.07 (-1.13%)

NEOS

Neos Therapeutics

$8.40

-0.3 (-3.45%)

SELB

Selecta Biosciences

$18.66

-0.18 (-0.96%)

PTGX

Protagonist Therapeutics

$16.28

-0.11 (-0.67%)

ITCI

Intra-Cellular

$19.23

-0.57 (-2.88%)

BLCM

Bellicum Pharmaceuticals

$11.54

-0.08 (-0.69%)

CALA

Calithera Biosciences

$15.45

-0.5 (-3.13%)

INO

Inovio

$6.31

0.02 (0.32%)

PRTA

Prothena

$63.73

-0.64 (-0.99%)

  • 27

    Sep

  • 27

    Sep

  • 04

    Oct

  • 05

    Oct

  • 30

    Jun

  • 30

    Jun

  • 28

    Sep

ENTA Enanta
$43.43

-0.07 (-0.16%)

07/11/17
JMPS
07/11/17
UPGRADE
JMPS
Outperform
Enanta upgraded on pipeline outlook at JMP Securities
As noted earlier, JMP Securities upgraded Enanta to Outperform from Market Perform. Analyst Liisa Bayko upgraded the stock based on her view of the potential of the company's early stage pipeline and FXR program. Target $40.
07/11/17
JMPS
07/11/17
UPGRADE
JMPS
Outperform
Enanta upgraded to Outperform from Market Perform at JMP Securities
09/14/17
RBCM
09/14/17
INITIATION
Target $54
RBCM
Outperform
Enanta initiated with an Outperform at RBC Capital
RBC Capital analyst Brian Abrahams started Enanta Pharmaceuticals with an Outperform rating and $54 price target.
ADXS Advaxis
$3.91

-0.36 (-8.43%)

11/30/16
CANT
11/30/16
INITIATION
Target $19
CANT
Buy
Advaxis initiated with a Buy at Cantor
Cantor analyst Mara Goldstein initiated Advaxis with a Buy and a $19 price target.
11/30/16
11/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Shutterfly (SFLY) initiated with a Buy at Aegis. 2. WageWorks (WAGE) initiated with a Buy at Chardan. 3. BorgWarner (BWA) initiated with a Buy at Jefferies. 4. Advaxis (ADXS) initiated with a Buy at Cantor. 5. Xtant (XTNT) initiated with a Buy at Aegis. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AWR American States Water
$50.68

-0.8 (-1.55%)

CDTX Cidara Therapeutics
$8.05

0.2 (2.55%)

07/28/17
WBBS
07/28/17
DOWNGRADE
WBBS
Cidara Therapeutics downgraded to Sell from Hold at WBB Securities
05/25/17
LEER
05/25/17
NO CHANGE
Target $16
LEER
Outperform
Cidara selloff creates favorable risk/reward in Q4 data, says Leerink
Leerink analyst Paul Matteis believes the selloff in shares of Cidara Therapeutics since the company discontinued its CD101 topical program in February creates a favorable risk/reward profile. Read-through to the CD101 IV program, with Phase 2 data coming in Q4, is an error, Matteis tells investors in a research note. Pharmacokinetic, preclinical, safety and historical echinocandin data point to a "solid odds of success" for the IV program, the analyst contends. He raised his CD101 IV odds of success to 60% from 50% and his price target for the shares to $16 from $13. Matteis reiterates an Outperform rating on Cidara.
04/26/17
BTIG
04/26/17
NO CHANGE
Target $20
BTIG
Buy
Cidara Therapeutics price target raised to $20 from $15 at BTIG
BTIG analyst Timothy Chiang raised his price target on Cidara Therapeutics to $20 from $15, as he believes Cidara's once-weekly dosed broad spectrum antifungal agent could become a best-in-class product in the prophylaxis market. Chiang keeps a Buy rating on Cidara shares.
08/11/17
WBBS
08/11/17
UPGRADE
WBBS
Hold
Cidara Therapeutics upgraded to Hold from Sell at WBB Securities
GEMP Gemphire Therapeutics
$9.60

-0.04 (-0.41%)

08/31/17
HCWC
08/31/17
INITIATION
Target $21
HCWC
Buy
Gemphire Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Ed Arce started Gemphire Therapeutics with a Buy rating and $21 price target. The share selloff following the ROYAL-1 results is overdone, Acre tells investors in a research note. The company's "novel approach" for nonalcoholic steatohepatitis, including a validated target, has so far been ignored by the Street, the analyst contends.
08/08/17
JEFF
08/08/17
NO CHANGE
Target $18
JEFF
Buy
Gemphire Therapeutics price target lowered to $18 from $32 at Jefferies
Jefferies analyst Matthew Andrews lowered his price target for Gemphire Therapeutics to $18 after reducing his probability of success estimate in heterozygous familial hypercholesterolemia and primary hypercholesterolemia with atherosclerotic cardiovascular disease to 50% from 70%. While gemcabene's absolute reduction of 17.2% is encouraging, the 11.7% placebo-adjusted is below expectations and "somewhat disappointing," Andrews tells investors in a research note. He keeps a Buy rating on Gemphire Therapeutics.
08/08/17
ADAM
08/08/17
NO CHANGE
Target $31
ADAM
Buy
Gemphire Therapeutics weakness overdone, says Canaccord
Canaccord analyst John Newman said Gemphire Therapeutics reported positive top line results for its Phase 2b ROYAL-1 trial, but they were slightly below expectations. He said the safety profile of gemcabene was clean, which is very important going forward. Newman said the recent weakness in the shares is overdone and he reiterated his Buy rating and $31 price target on Gemphire shares.
09/20/17
ADAM
09/20/17
NO CHANGE
Target $31
ADAM
Buy
Gemphire data support commercial viability of gemcabene, says Canaccord
After Gemphire Therapeutics reported that a combined data analysis showed a 21% LDL-C reduction for 600mg gemcabene, Canaccord analyst John Newman said he thinks the data support a clinically meaningful and commercially viable drug. The analyst, who expects gemcabene to continue to show a very clean safety profile and is interested to see if cardiovascular benefit will be part of the efficacy assessment of a Phase 3 trial, keeps a Buy rating and $31 price target on Gemphire shares.
ARRY Array BioPharma
$11.29

-0.03 (-0.27%)

09/11/17
CANT
09/11/17
NO CHANGE
Target $15
CANT
Overweight
Array BioPharma price target raised to $15 from $13 at Cantor
Cantor Fitzgerald analyst Mara Goldstein raised her price target for Array BioPharma to $15 saying the safety lead-in data from the Beacon study show "encouraging signs" of the potential to widen the market potential for binimetinib and encorafenib. These data "lend additional support" for the drugs as best-in-class for the treatment of advanced melanoma, Goldstein tells investors in a research note.The analyst has an Overweight rating on Array shares.
09/11/17
JPMS
09/11/17
NO CHANGE
Target $14
JPMS
Overweight
Array BioPharma price target raised to $14 from $11 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Array BioPharma to $14 following ESMO presentations for the company. Key presentations for Array at the conference include Columbus Part 2 results of binimetinib/encorafenib in BRAF melanoma and binimetinib/encorafenib/cetuximab Beacon results in BRAF colorectal cancer, Rama tells investors in a research note. The focus at ESMO was on Beacon colorectal cancer and the 41% overall response rate observed in the safety lead-in period "meaningfully beat expectations," the analyst writes. He believes Array shares should have rallied more than 7% on Friday. Rama reiterates an Overweight rating on the name.
09/08/17
PIPR
09/08/17
NO CHANGE
Target $14
PIPR
Overweight
Piper reiterates Overweight on Array after 'encouraging' data
Piper Jaffray analyst Edward Tenthoff says Array BioPharma and Pierre Fabre reported "encouraging" Phase III trial results in 30 BRAF-mutant colorectal cancer patients receiving binimetinib, encorafenib and cetuximab. The analyst expects approval of binimetinib and encorafenib in BRAF-mutant melanoma next year. He reiterates an Overweight rating on Array with a $14 price target.
09/20/17
PIPR
09/20/17
NO CHANGE
Target $18
PIPR
Overweight
Array BioPharma price target raised to $18 from $14 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Array BioPharma to $18 and reiterates an Overweight rating on the shares. The company recently strengthened its balance sheet ahead of next summer's approvals, Tenthoff tells investors in a research note. The FDA accepted new drug applications for binimetinib and encorafenib for BRAF-mutant melanoma and the analyst anticipates approval by the June 30 action date.
AUPH Aurinia Pharmaceuticals
$6.11

-0.07 (-1.13%)

09/13/17
ADAM
09/13/17
DOWNGRADE
Target $10
ADAM
Speculative Buy
Aurinia Pharmaceuticals downgraded to Speculative Buy from Buy at Canaccord
Canaccord analyst Neil Maruoka assumed coverage of Aurinia Pharmaceuticals and downgraded the stock to Speculative Buy from Buy, citing the high risks associated with biotech drug development. However, he believes the ongoing Phase III AURORA study has a good chance of success and sees Aurinia as undervalued based on the strength of data generated by voclosporin to date. Maruoka set a $10 price target on Aurinia shares.
03/03/17
HCWC
03/03/17
NO CHANGE
Target $12
HCWC
Buy
Aurinia Pharmaceuticals price target raised to $12 from $8 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target on Aurinia Pharmaceuticals to $12 from $8 after the company reported that treatment of lupus nephritis with voclosporin demonstrated a substantial further improvement at 48 weeks. Given this type of "rare" treatment effect change over time, Arce said his conviction has increased that voclosporin can quickly emerge as the new standard-of-care in lupus nephritis treatment and he keeps a Buy rating on Aurinia shares.
04/10/17
CANT
04/10/17
INITIATION
Target $14
CANT
Overweight
Aurinia Pharmaceuticals initiated with an Overweight at Cantor
Cantor initiated Aurinia Pharmaceuticals with an Overweight and a $14 price target.
03/06/17
FBRC
03/06/17
NO CHANGE
FBRC
FBR sees 'prime' merger environment for biotechs under Trump
Potential tax reform and FDA policy changes under President Trump could "prime the pump" for acquisitions of clinical-stage biotech companies by Big Pharma, FBR Capital analysts led by Chris Meekins tell investors in a research note. These police moves, coupled with the repeal of some taxes associated with the Affordable Care Act, are likely to increase funds for companies looking to make acquisitions, the analysts contend. Within its coverage universe, FBR sees TESARO (TSRO), Agile Therapeutics (AGRX), Kite Pharma (KITE), Juno Therapeutics (JUNO), Acceleron Pharma (XLRN), Abeona Therapeutics (ABEO), Aurinia Pharmaceuticals (AUPH), Geron (GERN) and Genocea Biosciences (GNCA) as "primary targets for those looking to make acquisitions."
NEOS Neos Therapeutics
$8.40

-0.3 (-3.45%)

07/31/17
CANT
07/31/17
INITIATION
Target $20
CANT
Overweight
Neos Therapeutics initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Neos Therapeutics with an Overweight rating and $20 price target. The analyst thinks the sales potential of the company's attention-deficit/hyperactivity disorder platform is underappreciated at current share levels.
08/01/17
08/01/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hain Celestial (HAIN) initiated with a Hold at Loop Capital. 2. Centennial Resource Development (CDEV) initiated with an Overweight at JPMorgan. 3. Neos Therapeutics (NEOS) initiated with an Overweight at Cantor. 4. Celldex (CLDX) assumed with a Buy at H.C. Wainwright. 5. SilverBow Resorces (SBOW) initiated with a Neutral at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/18/17
JMPS
09/18/17
NO CHANGE
Target $30
JMPS
Outperform
JMP says Neos has most complete offering of alternative dose ADHD drugs
JMP Securities analyst Jason Butler said Neos Therapeutics' approval of Adzenys ER Oral Solution further builds out the company's ADHD portfolio, giving it the most complete offering of alternative dose forms of the most widely prescribed drugs used to treat the condition. He keeps an Outperform rating and $30 price target on Neos shares.
09/15/17
BMOC
09/15/17
NO CHANGE
BMOC
Neos' Adzens ER approval 'rounds out ADHD portfolio,' says BMO Capital
BMO Capital analyst Gary Nachman said that while the FDA approval of Adzenys ER which was announced after the close was expected, it was good to see it get "over the goal line," as he believes it will "round out" Neos Therapeutics' ADHD portfolio. Nachman reiterated his Outperform rating and $14 price target on Neos shares.
SELB Selecta Biosciences
$18.66

-0.18 (-0.96%)

12/08/16
STFL
12/08/16
NO CHANGE
STFL
Selecta Biosciences price target raised to $32 from $23 at Stifel
Stifel analyst Thomas Shrader raised his price target on Selecta, saying that data on the company's SEL-212 treatment showed "initial proof of concept in humans with an acceptable safety profile for more serious disease states." He keeps a Buy rating on the shares.
PTGX Protagonist Therapeutics
$16.28

-0.11 (-0.67%)

07/21/17
BTIG
07/21/17
INITIATION
BTIG
Buy
Protagonist Therapeutics initiated with a Buy at BTIG
BTIG analyst Timothy Chiang started coverage of Protagonist with a $36 price target and a Buy rating. The analyst says that the company's oral peptide technology platform "shows promise for treating inflammatory bowel disease." He says that the mechanisms of action of two of the company's drugs "have already been clinically validated by approved treatments for patients that have not adequately responded to TNF-blockers and other existing treatments ."
06/01/17
LEER
06/01/17
NO CHANGE
Target $35
LEER
Outperform
Protagonist Therapeutics price target raised to $35 from $29 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Protagonist Therapeutics to $35 citing the "attractive" partnership for PTG-200. The analyst reiterates an Outperform rating on the shares.
05/30/17
BMOC
05/30/17
NO CHANGE
Target $45
BMOC
Outperform
Protagonist Therapeutics price target raised to $45 on licensing at BMO Capital
BMO Capital analyst Ian Somaiya raised Protagonist Therapeutics' price target to $45 from $34 and reiterated his Overweight rating citing the PGG-200 licensing deal with Janssen. The analyst said the deal increases the probability of clinical and regulatory success in Crohn's and ulcerative colitis and likely reduces the need for future financings.
05/31/17
BMOC
05/31/17
NO CHANGE
BMOC
Protagonist Therapeutics price target raised to $45 from $34 at BMO Capital
BMO Capital analyst M. Ian Somaiya increased his price target on Protagonist (PTGX) after the company reached a licensing deal with Johnson & Johnson (JNJ) for its PTG-200 drug. The analyst says that the deal increases the drug's chances of success , and he calls J&J "an ideal partner." Somaiya keeps an Outperform rating on the stock.
ITCI Intra-Cellular
$19.23

-0.57 (-2.88%)

08/30/17
LTCO
08/30/17
UPGRADE
Target $36
LTCO
Buy
Intra-Cellular upgraded to Buy with $36 target at Ladenburg
Ladenburg Thalmann analyst Christopher James upgraded Intra-Cellular Therapies to Buy from Neutral with a $36 price target. The shares in early trading are up 6%, or 99c, to $16.89. Current studies of lumateperone, which has a better side-effect profile than current schizophrenia medications, appear "sufficient for approval," James told investors earlier in a research note. He believes the drug could reach sales over $1B if Intra-Cellular can secure indications for bipolar depression and agitation in patients with dementia.
09/07/17
PIPR
09/07/17
UPGRADE
PIPR
Overweight
Intra-Cellular upgraded to Overweight from Neutral at Piper Jaffray
09/07/17
09/07/17
UPGRADE
Target $33

Overweight
Intra-Cellular upgraded to Overweight after schizophrenia data at Piper Jaffray
As previously reported, Piper Jaffray analyst Charles Duncan upgraded Intra-Cellular to Overweight from Neutral after the company reported data from its "switching" study of lumateperone in schizophrenia outpatients on approved antipsychotics. He said the trial gives "some of the strongest evidence to date" that lumateperone is differentiated on a range of side effects from the current standard of care. Duncan raised his price target on Intra-Cellular to $33 from $14.
09/08/17
COWN
09/08/17
NO CHANGE
Target $27
COWN
Outperform
Intra-Cellular price target raised to $27 from $20 at Cowen
Cowen analyst Ritu Baral raised her price target on Intra-Cellular to $27 from $20 following the release of top-line Phase 3 switch data on the long-term safety of its lead drug lumateperone in schizophrenia. She is cautious on the meaningfulness of superior efficacy signals but sees them as solid evidence of maintenance of clinical control with lumateperone. Baral maintained her Outperform rating on Intra-Cellular shares.
BLCM Bellicum Pharmaceuticals
$11.54

-0.08 (-0.69%)

03/08/17
WELS
03/08/17
INITIATION
WELS
Outperform
Bellicum Pharmaceuticals initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jim Birchenough started Bellicum Pharmaceuticals with an Outperform rating and $28-$31 price target range. The analyst believes the company's "switch technology" to turn cell therapeutics "on" and "off" will be at the forefront of a wave of new therapeutics.
06/23/17
LTCO
06/23/17
NO CHANGE
Target $31
LTCO
Buy
Bellicum selloff after 'strong' data unwarranted, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li said the updated data Bellicum presented on BPX-501 further strengthens its impressive profile and he sees a high probability for BPX-501 to meet the primary endpoint for an MAA filing. He believes the selloff in the stock as unwarranted and recommends taking advantage to build positions. Li keeps a Buy rating and $31 price target on Bellicum shares.
12/01/16
RAJA
12/01/16
INITIATION
Target $29
RAJA
Outperform
Bellicum Pharmaceuticals initiated with an Outperform at Raymond James
Raymond James analyst Reni Benjamin initiated Bellicum Pharmaceuticals with an Outperform and a $29 price target.
06/02/17
LTCO
06/02/17
NO CHANGE
Target $31
LTCO
Buy
Bellicum pullback a buying opportunity, says Ladenburg
Ladenburg Thalmann analyst Wangzhi Li views the recent pullback in shares of Bellicum Pharmaceuticals as a buying opportunity. The selloff is unwarranted and represents a lack of appreciation of the upcoming highlight of BPX-501 data on June 23, Li tells investors in a research note. The analyst does not see a fundamental event that triggered the selloff in the past week. Li keeps a Buy rating on Bellicum with a $31 price target.
CALA Calithera Biosciences
$15.45

-0.5 (-3.13%)

01/24/17
01/24/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Tableau (DATA) upgraded to Buy from Neutral at Citi with analyst Walter Pritchard saying consensus estimates for fiscal 2017 look low. Revenue transition impacted numbers more than the Street realized in 2016, Pritchard tells investors in a research note. The analyst raised his price target for the shares to $64 from $50. 2. Agrium (AGU) upgraded to Outperform from Market Perform at Cowen, while CF Industries (CF), Mosaic (MOS), and Potash (POT) were upgraded to Market Perform from Underperform. 3. Calithera Biosciences (CALA) upgraded to Neutral from Sell at Citi with analyst Robyn Karnauskas citing her conversation with management. Management now appears more open to partnering, Karnauskas tells investors in a research note. 4. Home Bancshares (HOMB) upgraded to Buy from Hold at Sandler O'Neill. 5. Amicus (FOLD) upgraded to Outperform from Neutral at Baird with analyst Michael Ulz saying the company removed two overhangs by providing regulatory clarity for Galafold in the U.S. as well as a strengthening its balance sheet. Ulz raised his price target to $10 from $7 on Amicus shares. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/03/17
LEER
04/03/17
INITIATION
Target $16
LEER
Outperform
Calithera Biosciences reinstated with an Outperform at Leerink
Leerink analyst Jonathan Chang resumed coverage of Calithera Biosciences with an Outperform rating and a $16 price target saying it is well positioned to execute with multiple sources of upside.
01/31/17
RHCO
01/31/17
NO CHANGE
RHCO
Incyte price target raised to $140 from $115 at SunTrust
SunTrust analyst Peter Lawson raised his price target on Incyte (INCY), citing "increased pipeline & technology value" as data releases and PDUFA dates approach. Additionally, the analyst is upbeat on the company's global collaboration deal with Calithera (CALA), saying that the deal expands Incyte's "reach into the (immuno-oncology) space." The analyst reiterates a Buy rating on Incyte.
06/12/17
HCWC
06/12/17
NO CHANGE
Target $19
HCWC
Buy
Calithera Biosciences price target raised to $19 from $14 at H.C. Wainwright
H.C. Wainwright analyst Shaunak Deepak raised his price target for Calithera Biosciences to $19 saying data suggest CB-1158 "demonstrates promising arginase inhibition." The analyst believes that twice-daily CB-1158 can effectively reduce arginase activity, resulting in "meaningful increases in plasma arginine activity and preliminary evidence of immune modulation." He keeps a Buy rating on Calithera.
INO Inovio
$6.31

0.02 (0.32%)

09/12/17
MAXM
09/12/17
NO CHANGE
MAXM
Inovio data positive, says Maxim
Maxim analyst Jason McCarthy says that the data on Inovio's (INO) INO-5150 for prostate cancer indicates that the drug "holds promise." He thinks that the company may find a new partner to replace Roche (RHHBY), and he keeps a $12 price target and a Buy rating on the shares.
09/06/17
SBSH
09/06/17
INITIATION
Target $10
SBSH
Buy
Inovio initiated with a Buy at Citi
Citi analyst Joel Beatty started Inovio Pharmaceuticals with a Buy rating and $10 price target. The shares are attractive as the company's differentiated immunotherapy platform has generated strong immune responses that can be used to specifically target a variety of cancers or infectious diseases, the analyst contends.
09/06/17
09/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Caterpillar (CAT) initiated with a Neutral at Seaport Global. 2. Liberty Global (LBTYA) initiated with a Buy at Deutsche Bank. 3. TransUnion (TRU) initiated with a Buy at SunTrust. 4. Inovio (INO) initiated with a Buy at Citi. 5. e.l.f. Beauty (ELF) initiated with a Buy at DA Davidson. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/08/17
PIPR
06/08/17
UPGRADE
Target $14
PIPR
Overweight
Piper upgrades Inovio to Overweight after lifting of clinical hold
Piper Jaffray analyst Charles Duncan upgraded Inovio Pharmaceuticals to Overweight from Neutral and raised his price target for the shares to $14 from $9. The lifting of the clinical hold and Phase III trial start of VGX-3100 reduces risk, Duncan tells investors in a research note. The analyst now has confidence that Inovio's early-stage efforts can eventually move into later-stage.
PRTA Prothena
$63.73

-0.64 (-0.99%)

08/16/17
EVER
08/16/17
INITIATION
EVER
Outperform
Prothena initiated with an Outperform at Evercore ISI
Evercore ISI analyst Josh Schimmer initiated Prothena with an Outperform and a $83 price target.
09/14/17
RBCM
09/14/17
INITIATION
Target $87
RBCM
Outperform
Prothena initiated with an Outperform at RBC Capital
Target $2RBC Capital analyst Kennen MacKay started Prothena with an Outperform rating and $87 price target.
07/10/17
JEFF
07/10/17
INITIATION
Target $100
JEFF
Buy
Prothena initiated with a Buy at Jefferies
Jefferies initiated Prothena with a Buy and a $100 price target.
07/11/17
JEFF
07/11/17
NO CHANGE
JEFF
Jefferies fundamentally positive on Biotechnology, lists top picks
Jefferies analyst Michael Yee rolled out coverage of 12 Biotechnology names in a 550 page research report. The analyst is "fundamentally positive" on the sector, believing investor interest in large-caps will pick up "as the road to repair slowly continues." He believes the smid-cap space is "becoming a good stock-pickers' market." Yee's top picks in Biotech space include Celgene (CELG), Vertex (VRTX), Spark Therapeutics (ONCE), Prothena (PRTA) and Intercept (ICPT). The analyst's best picks in the smid-cap space are Spark, Prothena, Intercept and FibroGen (FGEN).

TODAY'S FREE FLY STORIES

JPM

JPMorgan

$97.99

0.37 (0.38%)

18:12
10/18/17
10/18
18:12
10/18/17
18:12
Hot Stocks
SEC names JPMorgan exec Redfearn Director of Division of Trading and Markets »

The Securities and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

  • 22

    Oct

  • 23

    Oct

  • 02

    Nov

  • 05

    Nov

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

VZ

Verizon

$48.65

0.25 (0.52%)

18:10
10/18/17
10/18
18:10
10/18/17
18:10
Periodicals
Verizon targets spring start of delayed online TV service, Bloomberg says »

Verizon web TV…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:04
10/18/17
10/18
18:04
10/18/17
18:04
Hot Stocks
Steel Dynamics CEO optimistic conditions in place to benefit FY18 consumption »

CEO Mark Millet said:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

CE

Celanese

$104.03

-0.24 (-0.23%)

18:03
10/18/17
10/18
18:03
10/18/17
18:03
Earnings
Celanese increases price for acetyls and engineered materials products »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$36.44

0.27 (0.75%)

18:01
10/18/17
10/18
18:01
10/18/17
18:01
Earnings
Steel Dynamics reports Q3 ex-items EPS 66c, consensus 66c »

Reports Q3 revenue $2.4B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

OPTT

Ocean Power

$2.00

0.56 (38.89%)

17:59
10/18/17
10/18
17:59
10/18/17
17:59
Syndicate
Ocean Power files to sell common stock in 'best efforts' offering »

No amount was provided.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

, TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

17:58
10/18/17
10/18
17:58
10/18/17
17:58
Periodicals
Japan regulators probing Toshiba reporting practices for FY16/17, Nikkei says »

Japan's Securities…

TOSBF

Toshiba, also use TOSYY

$3.02

-0.03 (-0.98%)

TOSYY

Toshiba, also use TOSBF

$18.20

-0.11 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNW

Pinnacle West

$87.34

-0.42 (-0.48%)

17:53
10/18/17
10/18
17:53
10/18/17
17:53
Hot Stocks
Pinnacle West raises quarterly divided 6.1% to 69.5c per share »

Pinnacle West…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 05

    Nov

  • 05

    Nov

  • 05

    Nov

GILD

Gilead

$80.01

-0.23 (-0.29%)

17:46
10/18/17
10/18
17:46
10/18/17
17:46
Hot Stocks
FDA grants regulatory approval to Kite's Yescarta »

Kite, a Gilead company,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 26

    Oct

  • 06

    Nov

  • 12

    Feb

POT

Potash

$19.24

0.08 (0.42%)

, AGU

Agrium

$107.73

0.55 (0.51%)

17:37
10/18/17
10/18
17:37
10/18/17
17:37
Hot Stocks
Potash, Agrium: India approves proposed merger of equals transaction »

Potash Corporation of…

POT

Potash

$19.24

0.08 (0.42%)

AGU

Agrium

$107.73

0.55 (0.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$160.85

1.9 (1.20%)

17:36
10/18/17
10/18
17:36
10/18/17
17:36
Earnings
Valmont lowers FY17 adjusted EPS view to $6.90-$7.04 from $7.06, consensus $7.09 »

Annual guidance was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

NVO

Novo Nordisk

$50.13

0.82 (1.66%)

17:36
10/18/17
10/18
17:36
10/18/17
17:36
Hot Stocks
Novo Nordisk receives positive 16-0 vote from FDA Advisory Committe »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

CHFS

CHF Solutions

$8.30

-0.69 (-7.68%)

17:35
10/18/17
10/18
17:35
10/18/17
17:35
Syndicate
Breaking Syndicate news story on CHF Solutions »

CHF Solutions files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

VTGN

VistaGen Therapeutics

$1.31

0.04 (3.15%)

17:33
10/18/17
10/18
17:33
10/18/17
17:33
Syndicate
Breaking Syndicate news story on VistaGen Therapeutics »

VistaGen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLNW

Limelight Networks

$4.48

0.12 (2.75%)

, URI

United Rentals

$144.32

0.98 (0.68%)

17:32
10/18/17
10/18
17:32
10/18/17
17:32
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

LLNW

Limelight Networks

$4.48

0.12 (2.75%)

URI

United Rentals

$144.32

0.98 (0.68%)

KMI

Kinder Morgan

$18.58

-0.1 (-0.54%)

ADBE

Adobe

$153.00

2.62 (1.74%)

CNAT

Conatus

$5.15

0.05 (0.98%)

EBAY

eBay

$37.97

0.48 (1.28%)

HXL

Hexcel

$58.94

0.39 (0.67%)

CCI

Crown Castle

$100.96

-0.42 (-0.41%)

ESTE

Earthstone Energy

$10.54

-0.15 (-1.40%)

PEGI

Pattern Energy

RXDX

Ignyta

$16.25

1.9 (13.24%)

HCA

HCA Healthcare

$77.45

0.63 (0.82%)

KLAC

KLA-Tencor

$108.09

0.08 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 26

    Oct

  • 06

    Nov

  • 06

    Nov

  • 14

    Nov

  • 15

    Nov

  • 15

    May

  • 16

    May

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

VMI

Valmont

$160.85

1.9 (1.20%)

17:31
10/18/17
10/18
17:31
10/18/17
17:31
Earnings
Valmont reports Q3 adjusted EPS $1.56, consensus $1.61 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

AGEN

Agenus

$4.71

0.04 (0.86%)

17:31
10/18/17
10/18
17:31
10/18/17
17:31
Syndicate
Breaking Syndicate news story on Agenus »

Agenus files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

PEGI

Pattern Energy

17:31
10/18/17
10/18
17:31
10/18/17
17:31
Hot Stocks
Pattern Energy sees Q3 operating loss greater than Q316 »

On October 18, Pattern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

GE

General Electric

$23.12

-0.07 (-0.30%)

17:25
10/18/17
10/18
17:25
10/18/17
17:25
Periodicals
General Electric CEO cutting expenses, employees, WSJ reports »

General Electric's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

UNB

Union Bankshares

$47.10

-0.8 (-1.67%)

17:20
10/18/17
10/18
17:20
10/18/17
17:20
Hot Stocks
Union Bankshares sees Q418 charge of $3.2M on plan termination »

On October 18, the board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OIS

Oil States

$23.75

-0.2 (-0.84%)

17:19
10/18/17
10/18
17:19
10/18/17
17:19
Earnings
Oil States lowers Q3 revenue view to $164M from $165M-$185M, consensus $177.77M »

Oil States anticipates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

17:18
10/18/17
10/18
17:18
10/18/17
17:18
Hot Stocks
American Express says on track to cut $1B in costs by end of the year »

Says on track to cut $1B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 08

    Nov

OIS

Oil States

$23.75

-0.2 (-0.84%)

17:16
10/18/17
10/18
17:16
10/18/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Oil States »

Oil States lowers Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

AXP

American Express

$92.08

0.39 (0.43%)

17:08
10/18/17
10/18
17:08
10/18/17
17:08
Hot Stocks
American Express says 'right time' for leadership transition »

Comments taken from Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 22

    Oct

  • 08

    Nov

APRN

Blue Apron

$5.30

-0.08 (-1.49%)

17:06
10/18/17
10/18
17:06
10/18/17
17:06
Hot Stocks
Blue Apron to cut roughly 6% of total workforce, inclur roughly $3.5M in expense »

Blue Apron said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.